About AnHorn Medicines
AnHorn Medicines is a company based in Taipei (Taiwan) founded in 2020. AnHorn Medicines has raised $10 million across 1 funding round from investors including ITRI, Mega Financial Holding and Sunplus. AnHorn Medicines operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Taipei, Taiwan
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$10 M (USD)
in 1 rounds
-
Latest Funding Round
$10 M (USD), Series A
Apr 24, 2023
-
Investors
ITRI
& 5 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of AnHorn Medicines
AnHorn Medicines has successfully raised a total of $10M through 1 strategic funding round. The most recent funding activity was a Series A round of $10 million completed in April 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in AnHorn Medicines
AnHorn Medicines has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include ITRI, Mega Financial Holding and Sunplus.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
VC firm focusing on technology companies
|
Locked | Locked | Locked | |
|
Investment management services are offered by the company.
|
Locked | Locked | Locked | |
|
Not for profit R&D organisation engaged in applied research and technical services
|
Locked | Locked | Locked |
Investor details for AnHorn Medicines
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by AnHorn Medicines
Investment portfolio details for AnHorn Medicines
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - AnHorn Medicines
Detailed financials for AnHorn Medicines
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Anhorn Medicines Comparisons
Peer comparison for AnHorn Medicines
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of AnHorn Medicines
AnHorn Medicines operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of AnHorn Medicines
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Anhorn Medicines
Complete news archive for AnHorn Medicines
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AnHorn Medicines
AnHorn Medicines was founded in 2020 and raised its 1st funding round 3 years after it was founded.
AnHorn Medicines is headquartered in Taipei, Taiwan.
Chu Chiang Lin is the current CEO of AnHorn Medicines.
AnHorn Medicines is a funded company, having raised a total of $10M across 1 funding round to date.
Developer of therapeutics for cancer, neurology, and age-related diseases. It offers protein degradation drugs which include AH-001 for the treatment of androgenetic alopecia. It also provides drugs for prostate cancer, lymphoma, pancreatic, and colorectal cancer, neurodegenerative disease, and others.
AnHorn Medicines's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
AnHorn Medicines has 6 investors. Key investors include ITRI, Mega Financial Holding, Sunplus, Hongtai Electric, and Taiwania Capital.